Patient demographics and procedural details
| Characteristics | N (%) |
| Number of patients | 34 |
| Female gender | 22 (65) |
| Cyst characteristics | |
| Size (mm), median (range) | 35 (10–90) |
| Method of diagnosis | |
| Incidental finding | 20 (59) |
| Investigation for pain | 13 (38) |
| Investigation for raised ALP | 1 (3) |
| Already under surveillance | 16 (47) |
| Location of cyst | |
| Head | 13 (38) |
| Body | 12 (35) |
| Tail | 8 (24) |
| Uncinate | 1 (3) |
| Previous FNA | 6 (18) |
| Worrisome features on EUS* | 25 (74) |
| Procedural characteristics | |
| Prophylactic antibiotics | 34 (100) |
| Median number of forceps passes median (range) | 4 (1–10) |
| Technical success | 34 (100) |
| Specimen adequacy | 25 (74) |
| Final diagnosis | |
| IPMN | 12 (35) |
| MCN | 6 (18) |
| Inflammatory | 4 (12) |
| Indeterminate | 4 (12) |
| Lymphoepithelial cyst | 3 (9) |
| SCN | 3 (9) |
| NET | 2 (6) |
*Worrisome features were defined cyst size ≥3 cm, enhancing mural nodule ≥5 mm, thickened and enhancing cyst wall, main pancreatic duct (MPD) dilatation 5–9 mm, abrupt change in MPD calibre with distal pancreatic atrophy, presence of lymphadenopathy, elevated CA 19–9 or a cyst growth rate >5 mm/2 years.
ALP, alkaline phosphatase; EUS, endoscopic ultrasound; FNA, fine needle aspiration; IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; NET, neuroendocrine tumour; SCN, serous cystic neoplasm.